{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:26:01Z","timestamp":1787772361346,"version":"build-2784847793"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE:<\/jats:title>\n                    <jats:p>The purpose is to determine the advantages and role of supplemental deferred retinal laser treatment following intravitreal bevacizumab (IVB) monotherapy in cases of severe retinopathy of prematurity (ROP) requiring treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS:<\/jats:title>\n                    <jats:p>This is a retrospective study involving preterm infants diagnosed with treatment requiring ROP, treated initially with bevacizumab monotherapy who subsequently received deferred laser treatment during the study period from April 2019 to March 2021. Deferred laser treatment was done when recurrence of ROP or plus disease was noted or nonprogression of retinal vasculature was noted on two consecutive examinations over 2 weeks. The main outcomes measured were the ability of the treatment to prevent ROP progression or recurrence and anatomic outcome at the last follow-up visit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      Twenty-three eyes of 14 neonates were treated with a deferred laser treatment following the initial intravitreal injection of Bevacizumab. The mean postmenstrual age at which IVB was given was 34\n                      <jats:sup>+6<\/jats:sup>\n                      \u00b1 1\n                      <jats:sup>+3<\/jats:sup>\n                      weeks. The mean duration between IVB and retinal laser was 5\n                      <jats:sup>+3<\/jats:sup>\n                      \u00b1 3\n                      <jats:sup>+4<\/jats:sup>\n                      weeks. The mean weight at the time of injection was 1317.8 \u00b1 231.8 g. The mean weight of the infants at the time of the laser was 2050 \u00b1 813.9 g. None of the eyes developed recurrence or adverse anatomical outcomes following laser till the last available follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>In our small number of subjects, blinding complications of ROP were prevented by using a deferred laser treatment protocol following initial bevacizumab therapy in treatment requiring ROP. It is better suited in cases where compliance for long-term follow-up after bevacizumab therapy cannot be ensured.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ojo.ojo_120_22","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T13:56:24Z","timestamp":1716558984000},"page":"233-236","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Role of deferred retinal laser following intravitreal injection of bevacizumab in treatment of severe retinopathy of prematurity"],"prefix":"10.4103","volume":"16","author":[{"given":"Vishalakshi","family":"Bhat","sequence":"first","affiliation":[{"name":"Associate Professor, Department of Ophthalmology, SDM College of Medical Sciences and Hospital, Shri Dharmasthala Manjunatheshwara University, Dharwad, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankargouda H.","family":"Patil","sequence":"additional","affiliation":[{"name":"Professor, Department of Ophthalmology, SDM College of Medical Sciences and Hospital, Shri Dharmasthala Manjunatheshwara University, Dharwad, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,6,27]]},"reference":[{"issue":"Suppl 1","key":"R1-20240908","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/pr.2013.205","article-title":"Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010","volume":"74","author":"Blencowe","year":"2013","journal-title":"Pediatr Res"},{"key":"R2-20240908","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s12098-012-0707-y","article-title":"Retinopathy of prematurity in a rural neonatal intensive care unit in South India \u2013A prospective study","volume":"79","author":"Hungi","year":"2012","journal-title":"Indian J Pediatr"},{"key":"R3-20240908","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/bjophthalmol-2012-302801","article-title":"Comparison of profile of retinopathy of prematurity in semiurban\/rural and urban NICUs in Karnataka, India","volume":"97","author":"Murthy","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"R4-20240908","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/archopht.119.8.1110","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity:Ophthalmological outcomes at 10 years","volume":"119","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"R5-20240908","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1136\/bjo.2005.086330","article-title":"Diode laser versus cryotherapy in treatment of ROP","volume":"90","author":"O'Keefe","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"R6-20240908","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment:A randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R7-20240908","first-page":"233","article-title":"Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial","volume":"102","author":"Good","year":"2004","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R9-20240908","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archopht.123.7.991","article-title":"The international classification of retinopathy of prematurity revisited","volume":"123","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"R10-20240908","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.oret.2017.09.021","article-title":"Supplemental laser for eyes treated with bevacizumab monotherapy in severe retinopathy of prematurity","volume":"2","author":"Tandon","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"R11-20240908","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1007\/s10792-020-01543-w","article-title":"Prospective clinical study of two different treatment regimens of combined laser photocoagulation and intravitreal bevacizumab for retinopathy of prematurity:The Indian Twin Cities ROP study (ITCROPS) database report number 9","volume":"40","author":"Laveti","year":"2020","journal-title":"Int Ophthalmol"},{"key":"R12-20240908","first-page":"2376240","article-title":"Functional and structural outcomes of temporal zone ii-sparing laser photocoagulation combined with intravitreal bevacizumab in retinopathy of prematurity","author":"Seo","year":"2018","journal-title":"J Ophthalmol"},{"key":"R13-20240908","doi-asserted-by":"crossref","first-page":"F371","DOI":"10.1136\/fetalneonatal-2011-301121","article-title":"Aggressive posterior retinopathy of prematurity in large preterm babies in South India","volume":"97","author":"Shah","year":"2012","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"R14-20240908","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1038\/s41433-021-01413-4","article-title":"The results of intravitreal bevacizumab monotherapy for treating aggressive posterior retinopathy of prematurity and type 1 retinopathy of prematurity","volume":"35","author":"\u00c7\u00f6mez","year":"2021","journal-title":"Eye (Lond)"},{"key":"R15-20240908","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"R16-20240908","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.4103\/ijo.IJO_2581_20","article-title":"Combined intravitreal ranibizumab and zone I sparing laser ablation in infants with posterior zone I retinopathy of prematurity","volume":"69","author":"Parchand","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"R17-20240908","doi-asserted-by":"crossref","first-page":"860","DOI":"10.4103\/ijo.IJO_325_19","article-title":"Safety and efficacy of 532 nm frequency-doubled Nd-YAG green laser photocoagulation for treatment of retinopathy of prematurity","volume":"67","author":"Singh","year":"2019","journal-title":"Indian J Ophthalmol"},{"key":"R18-20240908","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1590\/S0004-27492008000100010","article-title":"Efficacy and safety of green laser photocoagulation for threshold retinopathy of prematurity","volume":"71","author":"Lira","year":"2008","journal-title":"Arq Bras Oftalmol"},{"key":"R19-20240908","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4103\/0301-4738.71689","article-title":"Technical aspects of laser treatment for acute retinopathy of prematurity under topical anesthesia","volume":"58","author":"Jalali","year":"2010","journal-title":"Indian J Ophthalmol"},{"key":"R20-20240908","doi-asserted-by":"crossref","first-page":"e013344","DOI":"10.1136\/bmjopen-2016-013344","article-title":"Anaesthesia modalities during laser photocoagulation for retinopathy of prematurity:A retrospective, longitudinal study","volume":"7","author":"Jiang","year":"2017","journal-title":"BMJ Open"},{"key":"R21-20240908","first-page":"400","article-title":"Aggressive posterior retinopathy of prematurity (APROP):LASER as the primary modality of treatment","volume":"16","author":"Narnaware","year":"2021","journal-title":"J Ophthalmic Vis Res"},{"key":"R22-20240908","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3928\/01913913-20210423-01","article-title":"An observational study of different treatment practices for aggressive posterior retinopathy of prematurity","volume":"58","author":"Kumari","year":"2021","journal-title":"J Pediatr Ophthalmol Strabismus"},{"issue":"Suppl 2","key":"R23-20240908","first-page":"S151","article-title":"Improving follow-up of infants during retinopathy of prematurity screening in rural areas","volume":"53","author":"Vinekar","year":"2016","journal-title":"Indian Pediatr"}],"container-title":["Oman Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ojo.ojo_120_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:40:38Z","timestamp":1787769638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ojo.ojo_120_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ojo.ojo_120_22","relation":{},"ISSN":["0974-620X","0974-7842"],"issn-type":[{"value":"0974-620X","type":"print"},{"value":"0974-7842","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"2022-05-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}